Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

The Food and Drug Administration (FDA) has expanded its approval of a ketamine nasal spray, Spravato (esketamine), as a standalone therapy for adults with treatment-resistant depression. Spravato was ...

The anesthetic ketamine is being hailed as a breakthrough therapy for people with post-traumatic stress disorder (PTSD), ...

were among the most effective treatments for treatment-resistant depression, usually defined as severe depressive symptoms that have not improved despite treatment with at least two standard ...

The small, Ireland-based company GH Research said its inhaled version of mebufotenin — a molecular cousin to psilocybin — was ...

“The depression was just a constant,” says Winograd, 54, who lives in Portland, Oregon. Around that time, a doctor friend told him about ketamine for treatment-resistant depression. It wasn ...

GH Research's inhaled psychedelic therapy GH001 has shown promise in a mid-stage trial in treatment-resistant depression (TRD ...

Spravato is classified as a Schedule III controlled substance and is only available through a restricted program called the Spravato REMS. The Food and Drug Administration (FDA) has approved ...

Nasal Spray Treating Major Depression Receives FDA Approval For Standalone Use The Food and Drug Administration has approved Johnson & Johnson's nasal spray as a standalone treatment for severe forms ...

an inhalable treatment for treatment-resistant depression (TRD), demonstrating a significant placebo-adjusted reduction in depression scores as measured by the MADRS scale on Day 8. The trial ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral antidepressants.